Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma.

Trial Profile

Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Panobinostat (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 30 May 2013 Status changed from recruiting to discontinued according to data presented at ASCO 2013.
    • 15 Nov 2012 Additional lead trial center identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top